A major new clinical trial involving more than 1,600 people has found that a GLP-1 pill form of the drug orforglipron works about as well as injectable semaglutide for people with type 2 diabetes .

Following an experiment conducted over 72 weeks and across 136 sites in 10 countries, a team led by obesity-medicine specialist Deborah Horn of the University of Texas reported that participants lost an average of 9.6 percent of their body weight on the highest dose of the drug.

That's comparable to the roughly 10 to 15 percent loss in body mass commonly seen in people with diabetes taking injectable semaglutide over a similar period.

Related: One Weight Loss Strategy Is 5x More Effective Than Ozempic, Trials Find

"Overall," the researchers write in their paper , "the findings ind

See Full Page